Fed Governor Adriana Kugler to resign
Haemonetics Corporation (NYSE:HAE), a global healthcare company with a market capitalization of $3.48 billion, has seen its stock price touch a 52-week low, reaching $69.2. According to InvestingPro analysis, the company maintains a strong financial position with a current ratio of 3.49, indicating robust liquidity. This latest price level reflects a significant downturn for the company, which has experienced a 1-year change with a decrease of 14.06%. Despite the decline, the company has demonstrated solid fundamentals with 9.84% revenue growth in the last twelve months. Analysts maintain a positive outlook, with price targets ranging from $85 to $125. The company, known for its blood management solutions, is now at a critical juncture as it attempts to rebound from this low point and regain market confidence. InvestingPro’s Fair Value analysis suggests the stock may be currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this healthcare leader.
In other recent news, Haemonetics Corporation has announced several significant developments. The company reported a robust second quarter for fiscal year 2025, with a 9% increase in revenue to $346 million, driven by a 31% surge in hospital revenue. Adjusted earnings per share rose 13%, leading to an increase in its organic growth guidance for the year.
Haemonetics also announced the sale of its Whole Blood division to GVS, S.p.A. This move aligns with the company’s intent to streamline its Whole Blood segment and is expected to finalize in Q1 CY25.
In terms of analyst coverage, JPMorgan initiated coverage on Haemonetics with an Overweight rating and a price target of $116, citing potential for revenue growth and robust cash flow. BTIG reaffirmed its Buy rating for Haemonetics, following the company’s announcement of the sale of its Whole Blood division.
The company also announced executive retirement plans, with Mr. Llorens stepping down from his role as Executive Vice President of Global Manufacturing and Supply Chain. Haemonetics is currently in the process of searching for a new executive to fill this position. These are the recent developments that investors should be aware of.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.